Table 2.

Adverse Event Reporting Following Immunization With Monovalent Measles Vaccine at 6 Months of Age and/or MMRII Vaccine at 12 Months of Age by Treatment Group

	Treatment group (number reporting AEa ≥ grade 3/number with any AE)
Adverse event reporting following immunization with:	2DNEG	2DPOS	1DNEG	1DPOS
Monovalent measles vaccine at 6 months of age
Number immunized	n = 65	n = 7	n = 0	n = 0
Subjects with follow-up	65	7	NAb	NA
Number of subjects reporting ≥1 adverse event	19	4	NA	NA
≥Grade 3/any adverse event
Local	0/13	0/2	NA	NA
Systemic	0/4	0/1	NA	NA
Feverc	0/4	0/0	NA	NA
Rash	0/1	0/1	NA	NA
Number of subjects with laboratory follow-up	n = 64	n = 7	NA	NA
Thrombocytopeniad	0/0	0/0	NA	NA
MMRII at 12 months of age
Number immunized	n = 61	n = 7	n = 27	n = 8
Subjects with follow-up	61	7	27	8
Number of subjects reporting ≥1 adverse events	17	2	9	4
≥Grade 3/any adverse event
Local	0/8	0/2	0/5	0/0
Systemic	0/5	0/0	0/5	0/4
Fever	0/7	0/0	1/5	1/2
Rash	0/1	0/0	0/0	0/0
Number of subjects with laboratory follow-up	n = 60	n = 7	n = 25	n = 8
Thrombocytopenia	0/0	0/0	0/0	0/0

NOTE. ^aAE indicates adverse event.

^bNA indicates not applicable.

^cGrade 3 fever = temperature of ≥104°F lasting between 2–5 days.

^dThrombocytopenia = decline in platelet count to <150,000/mm³.